Treace Medical Concepts, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John T. Treace
- Full Time Employees
- 477
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 203 Fort Wade Road Ponte Vedra FL United States of America 32081
- IPO Date
- Apr 23, 2021
- CIK
- 0001630627
- Website
- treace.com
- Similar Companies
- Business
- Treace Medical Concepts, Inc. (Nasdaq: TMCI) develops and markets minimally invasive foot and ankle medical devices designed for surgical correction of bunion deformities and related midfoot and forefoot pathologies. The company offers a comprehensive portfolio of proprietary orthopedic products, including the Lapiplasty 3D Bunion Correction System, the CrossRoads Fixation System, the SpeedPlate Fixation Systems, the Adductoplasty Lapidus Plate, the Hammertoe Fixation Systems, and the Mini-Bunion Kit; these systems utilize patented nitinol compression technology and titanium implants to enable reproducible, stable corrections with reduced complication risks. Treace serves orthopedic foot and ankle surgeons and podiatric surgeons primarily in the United States, with operations focused on the domestic market from its headquarters in Ponte Vedra Beach, Florida, where the company was founded in 2014. In recent developments, Treace expanded its product offerings with the launch of the Mini-Bunion System in 2024 and the Adductoplasty Lapidus Plate in early 2025, enhancing minimally invasive options for juvenile and adult bunion corrections; the company also strengthened its commercial infrastructure through surgeon education programs and reported robust procedure growth amid ongoing reimbursement advancements.
Treace Medical Concepts, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Treace Medical Concepts Q1 Earnings Call Highlights
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
Treace Medical Concepts Reports First Quarter 2026 Financial Results
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
Treace Announces First Surgical Cases with the SuperBite™ Compression Screw System
Treace Medical Concepts (NASDAQ:TMCI) and PAVmed (NASDAQ:PAVM) Head-To-Head Survey
Treace Medical Concepts Q4 Earnings Call Highlights
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results
Treace Highlights New Product Innovations and Updated Positive Clinical Study Data at the 2026 ACFAS Annual Scientific Conference
First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review
Treace Updates Date of Fourth Quarter and Full-Year 2025 Financial Results Release to February 27, 2026
301,100 Shares in Treace Medical Concepts, Inc. $TMCI Acquired by Acuitas Investments LLC
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
Treace Announces First Surgical Case Utilizing Lapiplasty® Lightning™ Technology
Treace Medical Concepts (NASDAQ:TMCI) Trading Down 0.8% – Time to Sell?
Treace Medical Secures Up to $175 Million in Debt Financing